NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PBYI

Puma Biotechnology Inc

Jun 30 • 04:00PM ET

3.43

Dollar change +0.10
Percentage change 3.00	%

Healthcare • Biotechnology • USA • NASD

Peers: INCY MRNA EXEL SRPT BPMC FGEN NKTR KPTI LGND AFMD

| Held by: VTI AVUV IWM VXF IWN JSML JSMD VTWO DFAS DFAT

Scroll to Statements

Index	RUT	P/E	4.46	EPS (ttm)	0.77	Insider Own	24.89%	Shs Outstand	49.62M	Perf Week	2.39%
Market Cap	170.26M	Forward P/E	14.60	EPS next Y	0.23	Insider Trans	-1.23%	Shs Float	37.28M	Perf Month	1.48%
Enterprise Value	138.80M	PEG	-	EPS next Q	0.09	Inst Own	53.40%	Short Float	7.18%	Perf Quarter	9.24%
Income	38.07M	P/S	0.73	EPS this Y	-21.77%	Inst Trans	3.79%	Short Ratio	7.65	Perf Half Y	13.58%
Sales	232.71M	P/B	1.75	EPS next Y	-51.55%	ROA	18.55%	Short Interest	2.68M	Perf YTD	12.46%
Book/sh	1.96	P/C	1.83	EPS next 5Y	-25.63%	ROE	51.41%	52W High	4.13 -16.95%	Perf Year	9.24%
Cash/sh	1.88	P/FCF	5.46	EPS past 3/5Y	- -	ROIC	35.33%	52W Low	2.22 54.16%	Perf 3Y	18.28%
Dividend Est.	-	EV/EBITDA	2.85	Sales past 3/5Y	-3.08% -3.28%	Gross Margin	72.40%	Volatility	3.17% 5.00%	Perf 5Y	-70.58%
Dividend TTM	-	EV/Sales	0.60	EPS Y/Y TTM	137.93%	Oper. Margin	16.01%	ATR (14)	0.16	Perf 10Y	-97.24%
Dividend Ex-Date	-	Quick Ratio	1.43	Sales Y/Y TTM	2.68%	Profit Margin	16.36%	RSI (14)	53.13	Recom	4.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.53	EPS Q/Q	159.66%	SMA20	-0.21%	Beta	1.27	Target Price	3.00
Payout	0.00%	Debt/Eq	0.64	Sales Q/Q	5.12%	SMA50	5.11%	Rel Volume	1.07	Prev Close	3.33
Employees	172	LT Debt/Eq	0.11	Earnings	May 08 AMC	SMA200	12.91%	Avg Volume	349.77K	Price	3.43
IPO	Apr 20, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	400.00% -3.25%	Trades		Volume	374,468	Change	3.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy	$11
Jun-25-20	Resumed	BofA/Merrill	Underperform	$9
Oct-08-19	Downgrade	Goldman	Neutral → Sell	$24 → $8
May-10-19	Downgrade	Citigroup	Buy → Neutral	$24
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$57 → $20
Jan-17-19	Initiated	Leerink Partners	Mkt Perform	$21
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight	$75
Sep-17-18	Initiated	Goldman	Sell	$42
May-11-18	Reiterated	Stifel	Buy	$95 → $87
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform	$92 → $108
Nov-10-17	Reiterated	Citigroup	Buy	$156 → $164
Oct-02-17	Reiterated	Stifel	Buy	$110 → $130
Sep-11-17	Reiterated	Credit Suisse	Outperform	$118 → $136
Jul-10-17	Resumed	Leerink Partners	Outperform	$115
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform	$60 → $88
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform	$40 → $60

Show Previous Ratings

Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks)
Jun-27-25 10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks)
Jun-25-25 11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 08:50AM	Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain (Zacks)
11:11AM	Loading…
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 10:51AM	Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane (Zacks)
Jun-12-25 11:30AM	Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? (Zacks)
Jun-11-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Jun-04-25 05:33PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.39%
May-28-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
May-26-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
May-12-25 08:50AM	Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock (Zacks)
May-09-25 09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks) -5.21%
08:48AM	PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates (Zacks)
03:39AM	Loading…
03:39AM	Puma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
May-08-25 05:55PM	Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates (Zacks)
04:52PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)
May-07-25 05:20PM	Puma Biotechnology Q1 2025 Earnings Preview (Seeking Alpha)
01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
08:10AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-06-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-05-25 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
May-01-25 08:05AM	Biogen Inc. (BIIB) Q1 Earnings Lag Estimates (Zacks)
Apr-30-25 12:00PM	Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
06:00AM	Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX (neratinib) for Breast Cancer Patients (GlobeNewswire)
Apr-28-25 03:03PM	Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
Apr-24-25 04:11PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results (Business Wire)
09:40AM	Loading…
Apr-23-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Apr-21-25 09:13AM	Is the Options Market Predicting a Spike in Puma Biotechnology Stock? (Zacks)
Apr-11-25 01:20PM	Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential (Seeking Alpha)
Apr-02-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-25 09:00AM	Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
Mar-20-25 12:23PM	Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why (Zacks)
Mar-18-25 04:35AM	Puma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right Now (Insider Monkey)
Mar-05-25 06:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
05:30PM	Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference (Business Wire)
Mar-03-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks) -6.42%
Feb-28-25 12:04PM	Q4 2024 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) +19.73%
02:34AM	Puma Biotechnology Inc (PBYI) Q4 2024 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Feb-27-25 05:29PM	Puma Biotech: Q4 Earnings Snapshot (Associated Press Finance) +7.94%
04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-26-25 04:15PM	Puma Biotechnology to Present at TD Cowens 45th Annual Health Care Conference (Business Wire)
Feb-13-25 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-05-25 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-03-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.45% +20.34%
Jan-01-25 09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks)
Dec-23-24 09:01AM	Puma Biotechnologys NERLYNX Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation (Business Wire)
Dec-04-24 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-28-24 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Nov-21-24 05:38AM	Puma commences Phase II trial of alisertib for breast cancer treatment (Clinical Trials Arena)
Nov-20-24 08:57AM	Puma Biotechnology Announces Initiation of ALISCA-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer (Business Wire)
Nov-08-24 02:27AM	Puma Biotechnology Inc (PBYI) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic ... (GuruFocus.com)
Nov-07-24 05:33PM	Puma Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Third Quarter 2024 Financial Results (Business Wire)
Nov-05-24 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-24-24 04:07PM	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Business Wire) +5.36%
Sep-12-24 07:59AM	Transforming Cancer Therapy Stocks to Watch In The Oncology Sector (News Direct)
Sep-03-24 04:15PM	Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-21-24 05:00AM	The Future of Medicine: Key Biotech Stocks to Watch (News Direct)
Aug-06-24 05:23PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.26% -7.44%
Aug-02-24 10:07AM	Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected (Zacks) +9.43%
Aug-01-24 05:04PM	Puma Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Second Quarter Financial Results (Business Wire)
Jul-23-24 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Jul-18-24 04:10PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results (Business Wire)
Jul-02-24 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.49%
Jun-07-24 05:37PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-03-24 02:33PM	Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer (Business Wire)
Jun-02-24 10:01AM	Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041) (Business Wire)
May-28-24 09:00AM	Puma Biotechnology to Join Russell 3000 Index (Business Wire)
May-24-24 11:57AM	Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why (Zacks)
May-23-24 05:15PM	Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting (Business Wire) -5.67%
May-20-24 09:59AM	Implied Volatility Surging for Puma Biotechnology (PBYI) Stock Options (Zacks) +6.72%
May-03-24 01:09PM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:31AM	Puma Biotechnology's (PBYI) Q1 Earnings and Revenues Beat (Zacks)
04:02AM	Puma Biotechnology Inc (PBYI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ... (GuruFocus.com)
May-02-24 09:55PM	PBYI Stock Earnings: Puma Biotechnology Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:05PM	Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:48PM	Puma Biotechnology Inc (PBYI) Reports Q1 Financial Results, Misses Analyst Revenue and EPS Forecasts (GuruFocus.com)
05:12PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)
Apr-26-24 11:40AM	What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings? (Zacks)
Apr-25-24 10:02AM	Earnings Preview: Puma Biotech (PBYI) Q1 Earnings Expected to Decline (Zacks)
Apr-18-24 04:15PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results (Business Wire)
Apr-11-24 06:00PM	Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-03-24 05:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-22-24 09:25AM	Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock? (Zacks)
Mar-20-24 08:30AM	Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer (Business Wire) +9.19%
Mar-02-24 08:29AM	Puma Biotechnology, Inc. (NASDAQ:PBYI) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 09:55AM	Q4 2023 Puma Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) -5.31%
09:40AM	Why Puma Biotech (PBYI) is a Top Value Stock for the Long-Term (Zacks)
09:39AM	Puma Biotechnology (PBYI) Q4 Earnings & Revenues Lag Estimates (Zacks)
Feb-29-24 04:41PM	Puma Biotechnology Inc (PBYI) Reports Positive Net Income for Q4 and Full Year 2023 (GuruFocus.com) -5.76%
04:40PM	Puma Biotech: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-27-24 06:30PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
11:51AM	Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store? (Zacks)

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILSON TROY EDWARD	Director	Jun 13 '25	Sale	3.40	10,800	36,720	43,550	Jun 17 07:55 PM
Stuglik Brian M	Director	Jun 13 '25	Sale	3.39	8,100	27,459	94,958	Jun 17 07:52 PM
Senderowicz Adrian	Director	Jun 13 '25	Sale	3.40	27,000	91,800	27,000	Jun 17 07:49 PM
MOYES JAY M	Director	Jun 13 '25	Sale	3.40	22,000	74,800	53,322	Jun 17 07:46 PM
Dorval Allison	Director	Jun 13 '25	Sale	3.40	11,610	39,474	75,390	Jun 17 07:43 PM
Cesano Alessandra	Director	Jun 13 '25	Sale	3.40	12,150	41,310	68,850	Jun 17 07:41 PM
WILSON TROY EDWARD	Director	Jun 13 '25	Proposed Sale	3.40	10,800	36,678		Jun 13 04:15 PM
Senderowicz Adrian	Director	Jun 13 '25	Proposed Sale	3.40	27,000	91,767		Jun 13 04:11 PM
Dorval Allison	Director	Jun 13 '25	Proposed Sale	3.40	11,610	39,437		Jun 13 04:10 PM
Cesano Alessandra	Director	Jun 13 '25	Proposed Sale	3.40	12,150	41,285		Jun 13 04:09 PM
Stuglik Brian M	Director	Jun 13 '25	Proposed Sale	3.39	8,100	27,497		Jun 13 04:07 PM
MOYES JAY M	Director	Jun 13 '25	Proposed Sale	3.40	22,000	74,756		Jun 13 04:04 PM
Ludwig Jeffrey Jerome	Former Officer	May 21 '25	Proposed Sale	3.42	55,882	191,310		May 21 03:00 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 02 '25	Sale	3.15	10,227	32,232	152,295	Jan 03 07:33 PM
Ludwig Jeffrey Jerome	Chief Commercial Officer	Jan 02 '25	Sale	3.15	9,437	29,743	108,951	Jan 03 07:31 PM
HUNT DOUGLAS M	See Remarks	Jan 02 '25	Sale	3.15	8,633	27,209	124,594	Jan 03 07:28 PM
AUERBACH ALAN H	President and CEO	Jan 02 '25	Sale	3.15	33,841	106,657	7,029,674	Jan 03 07:12 PM
NOUGUES MAXIMO F	Officer	Jan 02 '25	Proposed Sale	3.05	10,227	31,192		Jan 02 08:37 PM
Ludwig Jeffrey Jerome	Officer	Jan 02 '25	Proposed Sale	3.05	9,437	28,783		Jan 02 08:34 PM
HUNT DOUGLAS M	Officer	Jan 02 '25	Proposed Sale	3.05	8,633	26,331		Jan 02 08:33 PM
AUERBACH ALAN H	Officer	Jan 02 '25	Proposed Sale	3.05	33,841	103,215		Jan 02 08:30 PM
MILLER MICHAEL PATRICK	Director	Aug 12 '24	Sale	3.49	23,358	81,466	47,000	Aug 13 09:09 PM
MILLER MICHAEL PATRICK	Director	Aug 12 '24	Proposed Sale	3.76	23,358	87,826		Aug 12 09:27 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 17 '24	Sale	3.70	4,156	15,382	162,522	Jul 18 07:11 PM
Ludwig Jeffrey Jerome	Chief Commercial Officer	Jul 17 '24	Sale	3.70	2,598	9,615	118,388	Jul 18 07:06 PM
HUNT DOUGLAS M	See Remarks	Jul 17 '24	Sale	3.70	3,637	13,461	133,227	Jul 18 06:57 PM
AUERBACH ALAN H	President and CEO	Jul 17 '24	Sale	3.70	21,920	81,128	7,063,515	Jul 18 06:50 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 02 '24	Sale	3.27	5,295	17,307	166,678	Jul 02 09:22 PM
Ludwig Jeffrey Jerome	Chief Commercial Officer	Jul 02 '24	Sale	3.27	6,051	19,778	120,986	Jul 02 09:19 PM
HUNT DOUGLAS M	See Remarks	Jul 02 '24	Sale	3.27	4,349	14,215	136,864	Jul 02 09:15 PM
AUERBACH ALAN H	President and CEO	Jul 02 '24	Sale	3.27	18,885	61,726	7,085,435	Jul 02 09:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PBYI

Puma Biotechnology Inc

Upgrade your FINVIZ experience